• Bhausaheb B. Jankar Department of Pharmacology, Mahatma Gandhi Institute of Medical Science, Sewagram, Wardha
  • Devesh D. Gosavi Department of Pharmacology, Mahatma Gandhi Institute of Medical Science, Sewagram, Wardha


This study aims to review Lithium-associated ADRs during the treatment and its management. Databases of "Medline", "Google Scholar" and "PubMed" were searched with keywords for studies on ADRs of Lithium. All studies involving safety, monitoring and management of adverse drug reactions of Lithium were included. Most of the studies have reported that up to 50 to 80% of patients develop ADRs on Lithium. Common initial ADRs that develops within 1 w to 6 w are polydipsia and polyuria taken together (50 to 70%) followed by tremors (30 to 60%). GI symptoms (upset, abdominal pain and diarrhoea) up to 30% are other commoner ADRs of Lithium therapy and they mostly disappear later. Weight gain (20 to 50%), Hypothyroidism (14-34%) and Nephrotic diabetes insipidus develop during the long term Lithium therapy. Most of the ADRs are produced even at therapeutic range (0.6–1.2 mEq/l). As serum level increase, i.e. above 1.5 mEq/l, other serious ADRs like muscle fasciculation’s, worsening of tremor, dysarthria, ataxia, EPS, hallucination, and visual disturbances, seizures, coma, and death may be expected. Management of ADRs includes TDM, Dose reduction of Lithium, drugs like diuretics, beta blockers, SR preparations and sometimes withdrawal of the drug. We are concluded that Lithium can cause many ADRs depending upon dose and duration of therapy, hence, the Therapeutic Drug Monitoring of Lithium is necessary.

Keywords: Lithium, ADR, Bipolar disorder, TDM


Tripathi K. Essantial of Medical Pharmacology. 7th ed. New Delhi: Jaypee Brothers Medical; 2013. p. 415.
2. N Bennett MJBP. Clinical Pharmacology. 11th ed. Churchill Livingstone Elsevier; 2012. p. 329.
3. Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry 1999;175:336–9.
4. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011;25:289–98.
5. Livingstone C, Rampes H. Lithium: a review of its adverse metabolic effects. J Psychopharmacol 2006;20:347–55.
6. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987;10:329–45.
7. Movig KLL, Baumgarten R, Leufkens HGM. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003;182:319–23.
8. Bendz H, Aurell M, Balldin J, Mathé AA, Sjödin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 y or more on lithium. Nephrol Dial Transplant 1994;9:1250–4.
9. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithium-induced downregulation of Aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995;95:1838–45.
10. Smith DF BS. Sodium appetite in rats given lithium. Life Sci 1972;11:1021.
11. Weiss NM, Robertson GL. Effect of hypercalcemia and lithium therapy on the osmoregulation of thirst and vasopressin secretion. Vasopressin Raven Press: New York; 1985. p. 281–90.
12. Martin A. Clinical management of lithium-induced polyuria. Ment Hosp 1993;44:427–8.
13. Kosten TR, Forrest JN. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 1986;143:1563–8.
14. De Wardener HE, Herxheimer A. The effect of a high water intake on the kidney’s ability to concentrate the urine in man. 1957. J Am Soc Nephrol 2000;11:980–7.
15. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976;53:139–47.
16. Sachs G. Sanity versus vanity”: balancing the problem of weight gain and the benefits of psychotropic drugs. Ther Advan Psychoses 1999;7:842-7.
17. Peselow ED, Dunner DL, Fieve RR, Lautin A. Lithium carbonate and weight gain. J Affect Disord 1980;2:303–10.
18. A Venkoba Rao. A study of side effects of lithium. Indian J Psychiat 1983;25:87–93.
19. Vestergaard P, Licht RW, Brodersen A, Rasmussen NA, Christensen H, Arngrim T, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand 1998;98:310–5.
20. Becker T. Sex-specific differences in side effects of psychotropic drugs: Genes or gender ? Review Sex-specific differences in side effects of psychotropic drugs: genes or gender? 2016.
21. Teixeira NA, Karniol IG. The influence of age and sex on weight variation in rats treated chronically with lithium chloride. Acta Pharmacol Toxicol (Copenh) 1982;51:1–5.
22. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980;62:193–200.
23. Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989;82:611–7.
24. Vendsborg PB, Rafaelsen OJ. Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatr Scand 1973;49:601–10.
25. Vendsborg PB, Prytz S. Glucose tolerance and serum lipids in man after long-term lithium administration. Acta Psychiatr Scand 1976;53:64–9.
26. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr Ann 1999;29:580–94.
27. Biel MG, Peselow E, Mulcare L, Case BG, Fieve R. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007;9:435–42.
28. Vm S, Ds M. A longitudinal study of monitoring adverse drug reaction at psychiatric out-patient department in our tertiary care teaching hospital. Surendranagar 2014;4:49–52.
29. Gelenberg AJ JJ. Lithium tremor. J Clin Psychiatry 1995;56:283–7.
30. Johnson G. Lithium-early development, toxicity, and renal function. Neuropsychopharmacology 1998;19:200–5.
31. JK Trivedi, Arunlata PK Dalal, PK Sinha SS. A camparatie study of side-effects of lithium, carbamazepine, and haloperidol in acute mania. Indian J Psychiat 1996;38:248–9.
32. Trivedi JK, Sareen H, Yadav VS, Rai SB. Prescription pattern of mood stabilizers for bipolar disorder at a tertiary health care centre in north India. Indian J Psychiatry 2013;55:131–4.
33. Dols A, Sienaert P, Gerven H Van, Schouws S, Stevens A, Kupka R, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilisers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol 2013;28:287-96.
34. Jefferson JW GJ. Adverse reactions-neurological tremor. Prim Lithium Ther Williams Wilkins; 1977. p. 139–50.
35. Miodownik C, Witztum E, Lerner V. Lithium-induced tremor treated with vitamin B6:a preliminary case series. Int J Psychiatry Med 2002;32:103–8.
36. Bowden CL. Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 2003;6:269-75.
37. Stoll AL, Vuckovic A, McElroy SL. Histamine2-receptor antagonists for the treatment of valproate-induced gastrointestinal distress. Ann Clin Psychiatry 2011;3:301-4.
38. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet (London, England) 2012;379:721–8.
39. Yeung CK, Chan HHL. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004;5:3–8.
40. Remmer HI, Falk WE. Successful treatment of lithium-induced acne. J Clin Psychiatry 1986;47:48.
41. Pande AC, Max P, Donnelly RF. Lithium-associated with psoriasis. J Clin Psychiatry 1986;47:330.
42. Akkerhuis GW, Nolen WA. Lithium-associated psoriasis and omega-3 fatty acids. Am J Psychiatry 2003;160:1355.
43. Jafferany M. Lithium and skin: dermatologic manifestations of lithium therapy. Int J Dermatol 2008;47:1101–11.
44. McKinney PA, Finkenbine RD, DeVane CL. Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996;8:183–5.
45. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000;12:35–42.
46. Shopsin B. Effects oflithium on thyroid function: a review. Dis Nerv Syst 1970;31:237–44.
47. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002;51:305–11.
48. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002;27:104–7.
49. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007;30:363–6.
50. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005;87:313–7.
51. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health. BioMed Central 2006;2:23.
52. van Melick EJM, Wilting I, Meinders AE, Egberts TCG. Prevalence and determinants of thyroid disorders in elderly patients with affective disorders: lithium and nonlithium patients. Am J Geriatr Psychiatry 2010;18:395–403.
53. Emerson CH, Dyson WL, Utiger RD. Serum thyrotropin and thyroxine concentrations in patients receiving lithium carbonate. J Clin Endocrinol Metab 1973;36:338–46.
54. Lindstedt G, Nilsson LA, Walinder J, Skott A, Ohman R. On the prevalence, diagnosis and management of lithium-induced hypothyroidism in psychiatric patients. Br 1 Psychiat 1977;130:452–8.
55. Villeneuve A, Gautier J, Jus A, Perron D. Effect of lithium on thyroid in man. Lancet 1973;2:502.
56. Transb01 I, Christiansen C, Baastrup Pc. Endocrine effects of lithium. I Hypothyroidism, its prevalence in long-term treated patients. Acta Endocrinol 1978;87:759–67.
57. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism. J Clin Psychiatry 1999;60:249–55.
58. Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord 2015;3:28.
59. Okusa Mark D, Luz Jovita T, Crystal M. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994;97:383–9.
60. Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J, Baltimore W, W Lithium. In: Medical Toxicology: Diagnosis and Treatment of Human Poisoning. edited by; 1997. p. 1579.
61. Boton R, Gaviria M BD. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10:329–45.
62. Movig KLL, Baumgarten R, Leufkens HGM, Van Laarhoven JHM, Egberts ACG. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry. 2003;182(APR.):319–23.
63. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults--a systematic review. J Geriatr Psychiatry Neurol. 2012;25:51–61.
64. Vestergaard P, Amdisen A. Lithium treatment and kidney function. Acta Psychiatr Scand. 1981 Apr; 63:333–45.
65. Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. Eur Psychiatry. 2001 Jun; 16:199–206.
66. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 y or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant. 1996 Mar; 11:457–60.
67. Bucht G, Wahlin A. Renal Concentrating Capacity in Long-Term Lithium Treatment and after Withdrawal of Lithium. Acta Med Scand. 2009 Apr; 207(1-6):309–14.
68. TIMMER RT, SANDS JM. Lithium Intoxication. J Am Soc Nephrol. 1999 Mar; 10:666–74.
69. Demers RG, Heninger G. Electrocardiographic changes during lithium therapy. Dis Nerv Syst 1970;31:674–9.
70. Wilson J, Kraus E, Bailas M, Rakita L. Reversible sinus node abnormalities due to lithium carbonate therapy. N Engl J Med 1976;294:1223–4.
71. Eliasen P, Andersen M. Sinoatrical block during lithium treatment. Eur J Cardia I 1975;3:308–11.
72. Wellens H, Cats V, Duren D. Symptomatic sinus node abnormalities following lithium carbonate therapy. Am J Med 1975;59:285–7.
73. Jaffe CM. First-degree atrioventricular block during lithium carbonate treatment. Am J Psychiat 1977;134:88–9.
74. Tilkian AG, Schroeder JS, Kao J, Hultgren H. Effect of lithium on cardiovascular performance: report on extended ambulatory monitoring and exercise testi3ng before and during lithium therapy. Am J Cardia 1976;1:701–8.
75. Martínez-Arán A, Vieta E, Colom F, Torrent C, Reinares M, Goikolea JM, et al. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 2005;74:295–302.
76. Yeung CK, Chan HHL. Cutaneous adverse effects of lithium: Epidemiology and management. Vol. 5. American Journal of Clinical Dermatology; 2004. p. 3–8.
77. Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med 2000;30:1025–36.
78. Zubieta JK, Huguelet P, O’Neil RL, Giordani BJ. Cognitive function in euthymic Bipolar I Disorder. Psychiatry Res 2001;102:9–20.
79. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology (Berl) 2003;170:225–34.
80. López-Jaramillo C, Lopera-Vásquez J, Ospina-Duque J, García J, Gallo A, Cortez V, et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry 2010;71:1055–60.
81. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord 2010;12:87–94.
82. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011;198:351–6.
83. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. Oxford University Press; 2007. p. 1288.
84. Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315–31.
85. Demyttenaere K, De Fruyt J, Sienaert P. Psychotropics and sexuality. Int Clin Psychopharmacol 1998; 13 Suppl 6:S35–41.
86. Ghadirian AM, Annable L, Bélanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. Am J Psychiatry 1992;149:801–5.
87. Aizenberg D, Sigler M, Zemishlany Z, Weizman A. Lithium and male sexual function in affective patients. Clin Neuropharmacol 1996;19:515–9.
88. Zuncheddu C, Carpiniello B. Sexual dysfunctions and bipolar disorder: a study of patients submitted to a long-term lithium treatment. Clin Ther 2006;157:419–24.
89. Nora JJ, Nora AH, Toews WH. Letter: Lithium, Ebstein’s anomaly, and other congenital heart defects. Lancet (London, England) 1974;2:594–5.
90. Källén B, Tandberg A. Lithium and pregnancy. A cohort study on manic-depressive women. Acta Psychiatr Scand 1983;68:134–9.
91. Nemeroff CB. Safety of available agents used to treat bipolar disorder. J Clin Psychiatry 2003;64:532–9.
92. Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985;312:408–14.
93. Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008;3:1324–31.
94. Remmer HI FW. Successful treatment of lithium-induced acne. J Clin Psychiatry 1986;47:48.
95. Akkerhuis GW NW. Lithium-associated psoriasis and omega-3 fatty acids. Am J Psychiatry 2003;160:1355.
96. Mercke Y, Sheng H, Khan T LS. Hair loss in psycho-pharmacology. Ann Clin Psychiatry 2000;12:35–42.
614 Views | 1165 Downloads
How to Cite
Jankar, B. B., & Gosavi, D. D. (2016). ADVERSE DRUG REACTION OF LITHIUM CARBONATE-A REVIEW. Journal of Critical Reviews, 4(1), 1-6.
Pharmaceutical Sciences